These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34239906)

  • 1. Empagliflozin in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Pan D; Xu L; Chen P; Jiang H; Shi D; Guo M
    Front Cardiovasc Med; 2021; 8():683281. PubMed ID: 34239906
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis.
    Chambergo-Michilot D; Tauma-Arrué A; Loli-Guevara S
    Int J Cardiol Heart Vasc; 2021 Feb; 32():100690. PubMed ID: 33335975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
    Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
    Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
    Damman K; Beusekamp JC; Boorsma EM; Swart HP; Smilde TDJ; Elvan A; van Eck JWM; Heerspink HJL; Voors AA
    Eur J Heart Fail; 2020 Apr; 22(4):713-722. PubMed ID: 31912605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
    Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z
    Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Chinese Herbal Medicine for Heart Failure with Preserved Ejection Fraction: A Meta-Analysis.
    Mei J; Xu H; Xu FQ; Ju JQ
    Chin J Integr Med; 2019 Oct; 25(10):770-777. PubMed ID: 31127505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials.
    Guo Z; Wang L; Yu J; Wang Y; Yang Z; Zhou C
    Int J Clin Pharm; 2023 Jun; 45(3):547-555. PubMed ID: 36800144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Influence of Liraglutide for Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
    Zhang Y; Chen Q; Huang G; Wang L
    Heart Surg Forum; 2019 Oct; 22(6):E438-E444. PubMed ID: 31895026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis.
    Taylor RS; Walker S; Ciani O; Warren F; Smart NA; Piepoli M; Davos CH
    Health Technol Assess; 2019 May; 23(25):1-98. PubMed ID: 31140973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
    Abraham WT; Ponikowski P; Brueckmann M; Zeller C; Macesic H; Peil B; Brun M; Ustyugova A; Jamal W; Salsali A; Lindenfeld J; Anker SD;
    Eur J Heart Fail; 2019 Jul; 21(7):932-942. PubMed ID: 31218819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis.
    Shi Z; Gao F; Liu W; He X
    Front Cardiovasc Med; 2022; 9():869272. PubMed ID: 35445086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
    Abraham WT; Lindenfeld J; Ponikowski P; Agostoni P; Butler J; Desai AS; Filippatos G; Gniot J; Fu M; Gullestad L; Howlett JG; Nicholls SJ; Redon J; Schenkenberger I; Silva-Cardoso J; Störk S; Krzysztof Wranicz J; Savarese G; Brueckmann M; Jamal W; Nordaby M; Peil B; Ritter I; Ustyugova A; Zeller C; Salsali A; Anker SD
    Eur Heart J; 2021 Feb; 42(6):700-710. PubMed ID: 33351892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes.
    Aronow WS; Shamliyan TA
    Ann Transl Med; 2017 Dec; 5(23):455. PubMed ID: 29285488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data.
    Pufulete M; Maishman R; Dabner L; Higgins JPT; Rogers CA; Dayer M; MacLeod J; Purdy S; Hollingworth W; Schou M; Anguita-Sanchez M; Karlström P; Shochat MK; McDonagh T; Nightingale AK; Reeves BC
    Syst Rev; 2018 Jul; 7(1):112. PubMed ID: 30064502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
    Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction: A systematic review and meta-analysis.
    He Z; Yang L; Nie Y; Wang Y; Wang Y; Niu X; Bai M; Yao Y; Zhang Z
    Int J Cardiol; 2021 Dec; 345():83-88. PubMed ID: 34653575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis.
    Yang D; Zhang Y; Yan J; Liu M; An F
    Front Cardiovasc Med; 2022; 9():942125. PubMed ID: 36158789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
    Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.
    Rivas-Ruiz R; Villasis-Keever M; Miranda-Novales G; Castelán-Martínez OD; Rivas-Contreras S
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD009031. PubMed ID: 30887505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.
    Pokharel Y; Khariton Y; Tang Y; Nassif ME; Chan PS; Arnold SV; Jones PG; Spertus JA
    JAMA Cardiol; 2017 Dec; 2(12):1315-1321. PubMed ID: 29094152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.